• 1
    Goldstein SR. The effect of SERMs on the endometrium. Ann N Y Acad Sci 2001; 949: 23742.
  • 2
    Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 137188.
  • 3
    Colletta AA, Benson JR, Baum M. Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat 1994; 31: 59.
  • 4
    O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB. Inhibition of protein kinase C by tamoxifen. Cancer Res 1985; 45: 24625.
  • 5
    Mandlekar S, Kong AN. Mechanisms of tamoxifen-induced apoptosis. Apoptosis 2001; 6: 46977.
  • 6
    Guvakova MA, Surmacz E. Tamoxifen interferes with the insulin-like growth factor I receptor (IGF-IR) signaling pathway in breast cancer cells. Cancer Res 1997; 57: 260610.
  • 7
    Bogden JM, Eastman A, Bresnick E. A system in mouse liver for the repair of O6-methylguanine lesions in methylated DNA. Nucleic Acids Res 1981; 9: 3089103.
  • 8
    Pegg AE. Mammalian O6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res 1990; 50: 611929.
  • 9
    Srivenugopal KS, Yuan XH, Friedman HS, li-Osman F. Ubiquitination-dependent proteolysis of O6-methylguanine-DNA methyltransferase in human and murine tumor cells following inactivation with O6-benzylguanine or 1,3-bis(2-chloroethyl)-1-nitrosourea. Biochemistry 1996; 35: 132834.
  • 10
    Tano K, Dunn WC, Darroudi F, Shiota S, Preston RJ, Natarajan AT, Mitra S. Amplification of the DNA repair gene O6-methylguanine-DNA methyltransferase associated with resistance to alkylating drugs in a mammalian cell line. J Biol Chem 1997; 272: 132504.
  • 11
    Shiraishi A, Sakumi K, Sekiguchi M. Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase. Carcinogenesis 2000; 21: 187983.
  • 12
    Eadie JS, Conrad M, Toorchen D, Topal MD. Mechanism of mutagenesis by O6-methylguanine. Nature 1984; 308: 2013.
  • 13
    Snow ET, Foote RS, Mitra S. Base-pairing properties of O6-methylguanine in template DNA during in vitro DNA replication. J Biol Chem 1984; 259: 8095100.
  • 14
    Erickson LC, Laurent G, Sharkey NA, Kohn KW. DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells. Nature 1980; 288: 7279.
  • 15
    Kaina B, Fritz G, Mitra S, Coquerelle T. Transfection and expression of human O6-methylguanine-DNA methyltransferase (MGMT) cDNA in Chinese hamster cells: the role of MGMT in protection against the genotoxic effects of alkylating agents. Carcinogenesis 1991; 12: 185767.
  • 16
    Brent TP, Houghton PJ, Houghton JA. O6-Alkylguanine-DNA alkyltransferase activity correlates with the therapeutic response of human rhabdomyosarcoma xenografts to 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea. Proc Natl Acad Sci USA 1985; 82: 29859.
  • 17
    Margison GP, Povey AC, Kaina B, Santibanez Koref MF. Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 2003; 24: 62535.
  • 18
    Kokkinakis DM, Ahmed MM, Delgado R, Fruitwala MM, Mohiuddin M, bores-Saavedra J. Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents. Cancer Res 1997; 57: 53608.
  • 19
    Day RS,III, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM, Bynum GD. Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 1980; 288: 7247.
  • 20
    Dolan ME, Mitchell RB, Mummert C, Moschel RC, Pegg AE. Effect of O6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res 1991; 51: 336772.
  • 21
    Fischel JL, Barbe V, Berlion M, Formento P, Berrile J, Bizzari JP, Milano G. Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines. Eur J Cancer 1993; 29A: 226973.
  • 22
    Cocconi G, Bella M, Calabresi F, Tonato M, Canaletti R, Boni C, Buzzi F, Ceci G, Corgna E, Costa P. Treatment of metastatic malignant melanoma with dacarbazine plus tamoxifen. N Engl J Med 1992; 327: 51623.
  • 23
    da Rocha AB, Mans DR, Bernard EA, Ruschel C, Logullo AF, Wetmore LA, Leyva A, Schwartsmann G. Tamoxifen inhibits particulate-associated protein kinase C activity, and sensitises cultured human glioblastoma cells not to etoposide but to gamma-radiation and BCNU. Eur J Cancer 1999; 35: 8339.
  • 24
    Meyn RE, Murray D. Cell cycle effects of alkylating agents. Pharmacol Ther 1984; 24: 14763.
  • 25
    Myrnes B, Norstrand K, Giercksky KE, Sjunneskog C, Krokan H. A simplified assay for O6-methylguanine-DNA methyltransferase activity and its application to human neoplastic and non-neoplastic tissues. Carcinogenesis 1984; 5: 10614.
  • 26
    Kuo CC, Hsieh HP, Pan WY, Chen CP, Liou JP, Lee SJ, Chang YL, Chen LT, Chen CT, Chang JY. BPR0L075, a novel synthetic indole compound with antimitotic activity in human cancer cells, exerts effective antitumoral activity in vivo. Cancer Res 2004; 64: 46218.
  • 27
    Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 63240.
  • 28
    Brandi G, Paiardini M, Cervasi B, Fiorucci C, Filippone P, De MC, Zaffaroni N, Magnani M. A new indole-3-carbinol tetrameric derivative inhibits cyclin-dependent kinase 6 expression, and induces G1 cell cycle arrest in both estrogen-dependent and estrogen-independent breast cancer cell lines. Cancer Res 2003; 63: 402836.
  • 29
    Dewhurst LO, Gee JW, Rennie IG, MacNeil S. Tamoxifen, 17beta-oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. Br J Cancer 1997; 75: 8608.
  • 30
    Barkhem T, Haldosen LA, Gustafsson JA, Nilsson S. pS2 Gene expression in HepG2 cells: complex regulation through crosstalk between the estrogen receptor alpha, an estrogen-responsive element, and the activator protein 1 response element. Mol Pharmacol 2002; 61: 127383.
  • 31
    Gu WZ, Chen Z, Tahir SK, Rosenberg SH, Ng SC. Synergistic effect of paclitaxel and 4-hydroxytamoxifen on estrogen receptor-negative colon cancer and lung cancer cell lines. Anticancer Drugs 1999; 10: 895901.
  • 32
    Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat Rep 1984; 68: 14035.
  • 33
    Fischel JL, Barbe V, Berlion M, Formento P, Berrile J, Bizzari JP, Milano G. [Tamoxifen increases cytotoxic effects of fotemustine. Experimental results on cell lines of human melanoma]. Bull Cancer 1994; 81: 599604.
  • 34
    Wei LL, Katzenellenbogen BS, Robertson DW, Simpson DM, Katzenellenbogen JA. Nitrosourea and nitrosocarbamate derivatives of the antiestrogen tamoxifen as potential estrogen receptor-mediated cytotoxic agents in human breast cancer cells. Breast Cancer Res Treat 1986; 7: 7790.
  • 35
    Gibson NW, Hartley JA, Barnes D, Erickson LC. Combined effects of streptozotocin and mitozolomide against four human cell lines of the Mer+ phenotype. Cancer Res 1986; 46: 49958.
  • 36
    Grombacher T, Mitra S, Kaina B. Induction of the alkyltransferase (MGMT) gene by DNA damaging agents and the glucocorticoid dexamethasone and comparison with the response of base excision repair genes. Carcinogenesis 1996; 17: 232936.
  • 37
    Biswas T, Ramana CV, Srinivasan G, Boldogh I, Hazra TK, Chen Z, Tano K, Thompson EB, Mitra S. Activation of human O6-methylguanine-DNA methyltransferase gene by glucocorticoid hormone. Oncogene 1999; 18: 52532.
  • 38
    Belanich M, Pastor M, Randall T, Guerra D, Kibitel J, Alas L, Li B, Citron M, Wasserman P, White A, Eyre H, Jaeckle K, et al. Retrospective study of the correlation between the DNA repair protein alkyltransferase and survival of brain tumor patients treated with carmustine. Cancer Res 1996; 56: 7838.
  • 39
    Dolan ME, Moschel RC, Pegg AE. Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc Natl Acad Sci USA 1990; 87: 536872.
  • 40
    Friedman HS, Dolan ME, Moschel RC, Pegg AE, Felker GM, Rich J, Bigner DD, Schold SCJr. Enhancement of nitrosourea activity in medulloblastoma and glioblastoma multiforme. J Natl Cancer Inst 1992; 84: 192631.
  • 41
    Mitchell RB, Moschel RC, Dolan ME. Effect of O6-benzylguanine on the sensitivity of human tumor xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea and on DNA interstrand cross-link formation. Cancer Res 1992; 52: 11715.
  • 42
    Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, Winer EP, Panella TJ, Jordan VC, Fine RL. High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 1992; 84: 181116.
  • 43
    Boldogh I, Ramana CV, Chen Z, Biswas T, Hazra TK, Grosch S, Grombacher T, Mitra S, Kaina B. Regulation of expression of the DNA repair gene O6-methylguanine-DNA methyltransferase via protein kinase C-mediated signaling. Cancer Res 1998; 58: 39506.
  • 44
    Pickart CM. Mechanisms underlying ubiquitination. Annu Rev Biochem 2001; 70: 50333.
  • 45
    Finley D, Chau V. Ubiquitination. Annu Rev Cell Biol 1991; 7: 2569.
  • 46
    Ciechanover A, Schwartz AL. The ubiquitin-mediated proteolytic pathway: mechanisms of recognition of the proteolytic substrate and involvement in the degradation of native cellular proteins. FASEB J 1994; 8: 18291.
  • 47
    Hershko A, Ciechanover A. The ubiquitin system for protein degradation. Annu Rev Biochem 1992; 61: 761807.
  • 48
    Niture SK, Doneanu CE, Velu CS, Bailey NI, Srivenugopal KS. Proteomic analysis of human O6-methylguanine-DNA methyltransferase by affinity chromatography and tandem mass spectrometry. Biochem Biophys Res Commun 2005; 337: 117684.